Skip to main content
Top
Published in: Calcified Tissue International 6/2009

01-06-2009

Binge Alcohol-Induced Bone Damage is Accompanied by Differential Expression of Bone Remodeling-Related Genes in Rat Vertebral Bone

Authors: John J. Callaci, Ryan Himes, Kristen Lauing, Frederick H. Wezeman, Kirstyn Brownson

Published in: Calcified Tissue International | Issue 6/2009

Login to get access

Abstract

Binge alcohol-related bone damage is prevented by concurrent administration of bisphosphonates, suggesting an activation of bone resorption with patterned alcohol exposure. Although chronic alcohol abuse is known to cause osteopenia, little is known about the effects of binge drinking on bone metabolism. We examined the effects of binge alcohol exposure on the relationship between bone damage and modulation of bone remodeling-specific gene expression profiles. Our hypothesis was that bone damage observed in young adult rats after binge alcohol exposure is associated with differential expression of bone remodeling-related gene expression. We further hypothesized that this differential gene expression specific to bone remodeling (bone resorption or formation related) would be influenced by the duration of binge alcohol exposure. Binge alcohol (3 g/kg, i.p.) was administered on 3 consecutive days each week, for 1 or 4 weeks, to adult male rats. Matched control animals were injected with an equal volume of isotonic saline. Lumbar vertebrae, L4-5, were analyzed for the presence of bone damage by quantitative computed tomography and compressive strength analysis. Total RNA was isolated from an adjacent vertebrae (L3), and whole transcriptome gene expression data were obtained for each sample. The expression levels of a subset of bone formation and resorption-associated differentially expressed genes were validated by quantitative reverse transcriptase–polymerase chain reaction. Bone loss was not observed after 1 week of treatment but was observed after four binge alcohol cycles with a 23% decrease in cancellous bone mineral density and 17% decrease in vertebral compressive strength compared with control values (P < 0.05). We observed that the duration of binge alcohol treatment influenced the modulation of expression profiles for genes that regulate the bone formation process. The expression of key bone formation-related marker genes such as osteocalcin and alkaline phosphatase were significantly reduced (P < 0.05) after acute binge alcohol exposure, and expression of regulators of osteoblast activity such as bone morphogenetic proteins and parathyroid hormone receptor displayed significantly (P < 0.05) decreased differential expression. The expression of sclerostin, a key canonical Wnt inhibitory protein, was significantly increased after acute binge alcohol treatment. The expression of important regulators of osteoclast maturation and activity such as NF-κβ (nuclear factor κβ) ligand (RANKL) and interleukin-6 were significantly increased (P < 0.05) by binge alcohol, and osteoprotegerin levels were significantly decreased (P < 0.05) in vertebral bone. These results show that expression patterns of several key bone remodeling genes are significantly perturbed by binge alcohol treatment, suggesting that perturbation of gene expression associated with bone remodeling may be one mechanism contributing to the disruption of bone mass homeostasis and subsequent bone loss observed after binge alcohol exposure in rodents.
Literature
1.
go back to reference Bilke DD, Genant HK, Cann C, Recker RR, Halloran BP, Strewler GJ (1985) Bone disease in alcohol abuse. Ann Intern Med 103:42–48 Bilke DD, Genant HK, Cann C, Recker RR, Halloran BP, Strewler GJ (1985) Bone disease in alcohol abuse. Ann Intern Med 103:42–48
2.
go back to reference Farley JR, Fitzsimmons R, Taylor AK, Jorch UM, Lau KH (1988) Direct effects of ethanol on bone resorption and formation in vitro. Arch Biochem Biophys 238:305–314CrossRef Farley JR, Fitzsimmons R, Taylor AK, Jorch UM, Lau KH (1988) Direct effects of ethanol on bone resorption and formation in vitro. Arch Biochem Biophys 238:305–314CrossRef
3.
go back to reference Friday KE, Howard GA (1991) Ethanol inhibits human bone cell proliferation and function in vitro. Metabolism 40:562–565PubMedCrossRef Friday KE, Howard GA (1991) Ethanol inhibits human bone cell proliferation and function in vitro. Metabolism 40:562–565PubMedCrossRef
4.
go back to reference Wezeman FH, Emanuele MA, Emanuele NV, Moskal SF, Woods M, Suri M, Steiner J, LaPaglia N (1999) Chronic alcohol consumption during male rat adolescence impairs skeletal development through effects on osteoblast gene expression, bone mineral density and bone strength. Alcohol Clin Exp Res 23:1534–1542PubMed Wezeman FH, Emanuele MA, Emanuele NV, Moskal SF, Woods M, Suri M, Steiner J, LaPaglia N (1999) Chronic alcohol consumption during male rat adolescence impairs skeletal development through effects on osteoblast gene expression, bone mineral density and bone strength. Alcohol Clin Exp Res 23:1534–1542PubMed
5.
go back to reference Baran DT, Teitelbaum SL, Bergfeld MA, Parker G, Cruvant EM, Avioli LV (1980) Effect of alcohol ingestion on bone and mineral metabolism in rats. Am J Physiol E507–E510 Baran DT, Teitelbaum SL, Bergfeld MA, Parker G, Cruvant EM, Avioli LV (1980) Effect of alcohol ingestion on bone and mineral metabolism in rats. Am J Physiol E507–E510
6.
go back to reference Preedy VR, Sherwood RA, Akpoguma CO, Black D (1991) The urinary excretion of the collagen degradation markers pyridinoline and deoxypridinoline in an experimental rat model of alcoholic bone disease. Alcohol Alcohol 26:191–198PubMed Preedy VR, Sherwood RA, Akpoguma CO, Black D (1991) The urinary excretion of the collagen degradation markers pyridinoline and deoxypridinoline in an experimental rat model of alcoholic bone disease. Alcohol Alcohol 26:191–198PubMed
7.
go back to reference Zhang J, Dai J, Lin D-L, Habib P, Smith P, Murtha J, Fu Z, Yao Z, Qi Y, Keller ET (2002) Osteoprotegerin abrogates chronic alcohol ingestion-induced bone loss in mice. J Bone Miner Res 17:1256–1263PubMedCrossRef Zhang J, Dai J, Lin D-L, Habib P, Smith P, Murtha J, Fu Z, Yao Z, Qi Y, Keller ET (2002) Osteoprotegerin abrogates chronic alcohol ingestion-induced bone loss in mice. J Bone Miner Res 17:1256–1263PubMedCrossRef
8.
go back to reference Callaci JJ, Juknelis D, Patwardhan A, Sartori M, Frost N, Wezeman FH (2004) The effects of binge alcohol exposure on bone resorption and biomechanical and structural properties are offset by concurrent bisphosphonate treatment. Alcohol Clin Exp Res 28:182–191PubMedCrossRef Callaci JJ, Juknelis D, Patwardhan A, Sartori M, Frost N, Wezeman FH (2004) The effects of binge alcohol exposure on bone resorption and biomechanical and structural properties are offset by concurrent bisphosphonate treatment. Alcohol Clin Exp Res 28:182–191PubMedCrossRef
9.
go back to reference Stewart TL, Ralston SH (2000) Role of genetic factors in the pathogenesis of osteoporosis. J Endocrinol 166:235–245PubMedCrossRef Stewart TL, Ralston SH (2000) Role of genetic factors in the pathogenesis of osteoporosis. J Endocrinol 166:235–245PubMedCrossRef
10.
go back to reference Turner RT, Wronski TJ, Zhang M, Kidder LS, Bloomfield SA, Sibonga JD (1998) Effects of ethanol on gene expression in rat bone: transient dose-dependent changes in mRNA levels for bone matrix proteins, skeletal growth factors and cytokines are followed by reductions in bone formation. Alcohol Clin Exp Res 22:1591–1599PubMed Turner RT, Wronski TJ, Zhang M, Kidder LS, Bloomfield SA, Sibonga JD (1998) Effects of ethanol on gene expression in rat bone: transient dose-dependent changes in mRNA levels for bone matrix proteins, skeletal growth factors and cytokines are followed by reductions in bone formation. Alcohol Clin Exp Res 22:1591–1599PubMed
11.
go back to reference McHugh KP, Hodivala-Dilke K, Zheng MH, Namba N, Lam J, Novack D, Feng X, Ross FP, Hynes RO, Teitelbaum SL (2000) Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest 105:433–440PubMedCrossRef McHugh KP, Hodivala-Dilke K, Zheng MH, Namba N, Lam J, Novack D, Feng X, Ross FP, Hynes RO, Teitelbaum SL (2000) Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest 105:433–440PubMedCrossRef
12.
go back to reference Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, Wang H, Cundy T, Glorieux FH, Lev D, Zacharin M, Oexle K, Marcelino J, Suwairi W, Heeger S, Sabatakos G, Apte S, Adkins WN, Allgrove J, Arslan-Kirchner M, Batch JA, Beighton P, Black GC, Boles RG, Boon LM, Borrone C, Brunner HG, Carle GF, Dallapiccola B, De Paepe A, Floege B, Halfhide ML, Hall B, Hennekam RC, Hirose T, Jans A, Jüppner H, Kim CA, Keppler-Noreuil K, Kohlschuetter A, LaCombe D, Lambert M, Lemyre E, Letteboer T, Peltonen L, Ramesar RS, Romanengo M, Somer H, Steichen-Gersdorf E, Steinmann B, Sullivan B, Superti-Furga A, Swoboda W, van den Boogaard MJ, Van Hul W, Vikkula M, Votruba M, Zabel B, Garcia T, Baron R, Olsen BR, Warman ML, Osteoporosis-Pseudoglioma Syndrome Collaborative Group (2001) LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107:513–523PubMedCrossRef Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, Wang H, Cundy T, Glorieux FH, Lev D, Zacharin M, Oexle K, Marcelino J, Suwairi W, Heeger S, Sabatakos G, Apte S, Adkins WN, Allgrove J, Arslan-Kirchner M, Batch JA, Beighton P, Black GC, Boles RG, Boon LM, Borrone C, Brunner HG, Carle GF, Dallapiccola B, De Paepe A, Floege B, Halfhide ML, Hall B, Hennekam RC, Hirose T, Jans A, Jüppner H, Kim CA, Keppler-Noreuil K, Kohlschuetter A, LaCombe D, Lambert M, Lemyre E, Letteboer T, Peltonen L, Ramesar RS, Romanengo M, Somer H, Steichen-Gersdorf E, Steinmann B, Sullivan B, Superti-Furga A, Swoboda W, van den Boogaard MJ, Van Hul W, Vikkula M, Votruba M, Zabel B, Garcia T, Baron R, Olsen BR, Warman ML, Osteoporosis-Pseudoglioma Syndrome Collaborative Group (2001) LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107:513–523PubMedCrossRef
13.
go back to reference Himes R, Wezeman FH, Callaci JJ (2008) Identification of novel bone-specific targets of binge alcohol and ibandronate by transcriptome analysis. Alcohol Clin Exp Res 3:1167–1180CrossRef Himes R, Wezeman FH, Callaci JJ (2008) Identification of novel bone-specific targets of binge alcohol and ibandronate by transcriptome analysis. Alcohol Clin Exp Res 3:1167–1180CrossRef
14.
go back to reference Read JP, Beattie M, Chamberlain R, Merrill JE (2008) Beyond the “Binge” threshold: heavy drinking patterns and their association with alcohol involvement indices in college students. Addict Behav 33:225–234PubMedCrossRef Read JP, Beattie M, Chamberlain R, Merrill JE (2008) Beyond the “Binge” threshold: heavy drinking patterns and their association with alcohol involvement indices in college students. Addict Behav 33:225–234PubMedCrossRef
15.
go back to reference Callaci JJ, Juknelis D, Patwardhan D, Wezeman FH (2006) Binge alcohol treatment increases vertebral bone loss following ovariectomy: compensation by intermittent parathyroid hormone. Alcohol Clin Exp Res 30:665–672PubMedCrossRef Callaci JJ, Juknelis D, Patwardhan D, Wezeman FH (2006) Binge alcohol treatment increases vertebral bone loss following ovariectomy: compensation by intermittent parathyroid hormone. Alcohol Clin Exp Res 30:665–672PubMedCrossRef
16.
go back to reference Wezeman FH, Juknelis D, Himes R, Callaci JJ (2007) Vitamin D and ibandronate prevent cancellous bone loss associated with binge alcohol treatment in male rats. Bone 41:639–645PubMedCrossRef Wezeman FH, Juknelis D, Himes R, Callaci JJ (2007) Vitamin D and ibandronate prevent cancellous bone loss associated with binge alcohol treatment in male rats. Bone 41:639–645PubMedCrossRef
17.
go back to reference Nation JR, Burkey RT, Grover CA (1993) Lead/ethanol interactions. II: phamacokinetics. Alcohol 10:363–367PubMedCrossRef Nation JR, Burkey RT, Grover CA (1993) Lead/ethanol interactions. II: phamacokinetics. Alcohol 10:363–367PubMedCrossRef
18.
go back to reference Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2-−ΔΔCT method. Methods 25:402–408PubMedCrossRef Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2-−ΔΔCT method. Methods 25:402–408PubMedCrossRef
19.
go back to reference Penland S, Hoplight B, Obernier J, Crews FT (2001) Effects of nicotine on ethanol dependence and brain damage. Alcohol 24:45–54PubMedCrossRef Penland S, Hoplight B, Obernier J, Crews FT (2001) Effects of nicotine on ethanol dependence and brain damage. Alcohol 24:45–54PubMedCrossRef
20.
go back to reference Becker HC (2000) Animal models of alcohol withdrawal. Alcohol Res Health 24:105–113PubMed Becker HC (2000) Animal models of alcohol withdrawal. Alcohol Res Health 24:105–113PubMed
22.
go back to reference Chen JR, Haley RL, Hidestrand M, Shankar K, Liu X, Lumpkin CK, Simpson PM, Badger TM, Ronis MJ (2006) Estradiol protects against ethanol-induced bone loss by inhibiting up-regulation of receptor activator of nuclear factor-kappaβ ligand in osteoblasts. J Pharmacol Exp Ther 319:1182–1190PubMedCrossRef Chen JR, Haley RL, Hidestrand M, Shankar K, Liu X, Lumpkin CK, Simpson PM, Badger TM, Ronis MJ (2006) Estradiol protects against ethanol-induced bone loss by inhibiting up-regulation of receptor activator of nuclear factor-kappaβ ligand in osteoblasts. J Pharmacol Exp Ther 319:1182–1190PubMedCrossRef
23.
go back to reference Torricelli P, Fini M, Giavaresi G, Borsari V, Rimondini L, Rimondini R, Carrassi A, Giardino R (2007) Intermittent exposure to ethanol vapor affects osteoblast behavior more severely than estrogen deficiency does; in vitro study on rat osteoblasts. Toxicology 237:168–176PubMedCrossRef Torricelli P, Fini M, Giavaresi G, Borsari V, Rimondini L, Rimondini R, Carrassi A, Giardino R (2007) Intermittent exposure to ethanol vapor affects osteoblast behavior more severely than estrogen deficiency does; in vitro study on rat osteoblasts. Toxicology 237:168–176PubMedCrossRef
24.
go back to reference Hannan MT, Felson DT, Dawson-Hughes B, Tucker KL, Cupples LA, Wilson PW, Kiel DP (2000) Risk factors for longitudinal bone loss in elderly men and women: the Framingham Osteoporosis Study. Bone Miner Res 15:710–720CrossRef Hannan MT, Felson DT, Dawson-Hughes B, Tucker KL, Cupples LA, Wilson PW, Kiel DP (2000) Risk factors for longitudinal bone loss in elderly men and women: the Framingham Osteoporosis Study. Bone Miner Res 15:710–720CrossRef
25.
go back to reference Sampath TK, Maliakal JC, Hauschka PV, Jones WK, Sasak H, Tucker RF, White KH, Coughlin JE, Tucker MM, Pang RH (1992) Recombinant human osteogenic protein-1 (hOP-1) induces new bone formation in vivo with a specific activity comparable with natural bovine osteogenic protein and stimulates osteoblast proliferation and differentiation in vitro. J Biol Chem 267:20352–20362PubMed Sampath TK, Maliakal JC, Hauschka PV, Jones WK, Sasak H, Tucker RF, White KH, Coughlin JE, Tucker MM, Pang RH (1992) Recombinant human osteogenic protein-1 (hOP-1) induces new bone formation in vivo with a specific activity comparable with natural bovine osteogenic protein and stimulates osteoblast proliferation and differentiation in vitro. J Biol Chem 267:20352–20362PubMed
26.
go back to reference van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE, ten Dijke P, Löwik CW (2004) Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 199:805–814PubMedCrossRef van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE, ten Dijke P, Löwik CW (2004) Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 199:805–814PubMedCrossRef
27.
go back to reference Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA (2003) Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 22:6267–6276PubMedCrossRef Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA (2003) Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 22:6267–6276PubMedCrossRef
28.
go back to reference Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L (1997) A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390(6656):175–179PubMedCrossRef Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L (1997) A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390(6656):175–179PubMedCrossRef
29.
go back to reference Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309–319PubMedCrossRef Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309–319PubMedCrossRef
30.
go back to reference Johnson ML (2004) The high bone mass family—the role of Wnt/Lrp5 signaling in the regulation of bone mass. J Muskuloskelet Neuronal Interact 4:135–138 Johnson ML (2004) The high bone mass family—the role of Wnt/Lrp5 signaling in the regulation of bone mass. J Muskuloskelet Neuronal Interact 4:135–138
31.
go back to reference Dai J, Lin D, Zhang J, Habib P, Smith P, Murtha J, Fu Z, Yao Z, Qi Y, Keller ET (2000) Chronic alcohol ingestion induces osteoclastogenesis and bone loss through IL-6 in mice. J Clin Invest 106:887–895PubMedCrossRef Dai J, Lin D, Zhang J, Habib P, Smith P, Murtha J, Fu Z, Yao Z, Qi Y, Keller ET (2000) Chronic alcohol ingestion induces osteoclastogenesis and bone loss through IL-6 in mice. J Clin Invest 106:887–895PubMedCrossRef
32.
go back to reference Palmqvist P, Persson E, Conaway HH, Lerner UH (2002) IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. J Immunol 169:3353–3362PubMed Palmqvist P, Persson E, Conaway HH, Lerner UH (2002) IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. J Immunol 169:3353–3362PubMed
33.
go back to reference Wezeman FH, Juknelis D, Frost N, Callaci JJ (2003) spine mineral density and vertebral body height are altered by alcohol consumption in growing male and female rats. Alcohol 31:1–6CrossRef Wezeman FH, Juknelis D, Frost N, Callaci JJ (2003) spine mineral density and vertebral body height are altered by alcohol consumption in growing male and female rats. Alcohol 31:1–6CrossRef
Metadata
Title
Binge Alcohol-Induced Bone Damage is Accompanied by Differential Expression of Bone Remodeling-Related Genes in Rat Vertebral Bone
Authors
John J. Callaci
Ryan Himes
Kristen Lauing
Frederick H. Wezeman
Kirstyn Brownson
Publication date
01-06-2009
Publisher
Springer-Verlag
Published in
Calcified Tissue International / Issue 6/2009
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-009-9240-z

Other articles of this Issue 6/2009

Calcified Tissue International 6/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine